Key takeaways
- Stanford researchers found that roughly 1 in 10 people carry genetic variants that blunt GLP-1 drug effectiveness.
What happened
Newly highlighted consumer genetic data and medical research are helping to explain why a portion of patients fail to lose weight on GLP-1 medications. Analysis from the 23andMe Research Institute and Stanford Medicine has identified distinct genetic variants and behavioral profiles—such as emotional eating—that can heavily blunt the effectiveness of blockbuster weight-loss shots.
Why it matters
For patients paying out-of-pocket for telehealth weight-loss treatments, failing to lose weight is both a clinical disappointment and a major financial drain. Since brand-name GLP-1 drugs like Wegovy and Zepbound retail for upwards of $1,000 to $1,300 per month without insurance, understanding why some people lose more than 20% of their body weight while others lose almost nothing is critical.
Identifying these biological and behavioral roadblocks helps buyers troubleshoot their treatment early, potentially swapping medications or adding supportive therapies before wasting thousands of dollars.
What the data says
The data reveals that GLP-1 response is far from uniform:
- The Genetics Gap: Stanford Medicine researchers identified genetic variants carried by roughly 1 in 10 people (10%) that appear to blunt the effects of GLP-1 drugs. Interestingly, these individuals naturally produce more of the GLP-1 hormone themselves but are less responsive to the therapeutic injections.
- The 23andMe Findings: Broad data from the 23andMe Research Institute confirms a massive variance in patient outcomes, showing that while some patients shed over 20% of their body weight, others lose less than 5% or even gain weight while taking the exact same dose.
- Behavioral Patterns: Research out of Japan indicates that patients who overeat because food looks and smells appealing (external eaters) lose more weight on GLP-1s. Conversely, emotional eaters—who eat to ease stress, anxiety, or bad moods—see significantly weaker weight-loss results.
- Demographics: Gender remains a primary demographic predictor. On average, women lose more weight on these medications than men, while patients living with Type 2 diabetes generally shed less weight than those without the condition.
How it compares
When confronting a lack of weight loss, patients face different clinical and financial decisions depending on the specific GLP-1 molecule they are taking.
Semaglutide (the active ingredient in Ozempic and Wegovy) is a single-receptor agonist targeting only GLP-1. Tirzepatide (the active ingredient in Mounjaro and Zepbound) is a dual-receptor agonist targeting both GLP-1 and GIP. Clinical trials have consistently shown that tirzepatide leads to greater average weight loss, making it a common "step-up" option for patients who do not respond well to semaglutide.
For online buyers, the cost of switching can vary. While brand-name Zepbound is highly expensive, many telehealth platforms offer compounded versions of both peptides. Compounded semaglutide is widely available through online providers starting around $150 to $250 per month, while compounded tirzepatide typically costs $300 to $500 per month due to the more complex dual-peptide formulation.
How this fits the bigger picture
This genetic and behavioral research adds hard science to a phenomenon well-known to clinicians: non-response is a real biological hurdle, not a personal failure. In our previous guide on why am I not losing weight on Wegovy or Ozempic, we highlighted that approximately 10% to 17% of patients are considered clinical "non-responders" who fail to achieve meaningful weight loss on standard semaglutide doses.
Rather than waiting for a complex DNA test, medical experts point out that a patient's early response is the most reliable predictor of long-term success. According to Dr. Anthony Puopolo, a board-certified physician and chief medical officer at LifeMD, losing at least 5 pounds in the first three months "outperforms any known genetic marker" in predicting whether the drug will work long-term.
For those identified as emotional eaters, the GLP-1 hormone alone may not be enough to override the psychological triggers of overeating. Dr. Puopolo notes that this is not a reason to stop treatment, but rather a signal that patients may need to combine their GLP-1 therapy with behavioral therapies, cognitive behavioral therapy, or complementary medications like naltrexone or bupropion.
This multi-pronged approach explains why many telehealth platforms are moving toward comprehensive weight-management programs rather than simply shipping vials. Furthermore, as the clinical community continues to study the diverse pathways of metabolic health, researchers are looking at novel combinations, such as pairing GLP-1s with gut-health therapies. For example, Novo Nordisk is currently partnering on synbiotic gut supplements to see if modifying the microbiome can boost overall metabolic response.
What happens next
While the dream of a simple pre-treatment saliva test is highly appealing to telehealth buyers looking to avoid costly trial-and-error, a clinically viable genetic test is not close to commercial readiness.
In the immediate future, clinicians are encouraged to use rapid, minutes-long questionnaires—such as the Dutch Eating Behavior Questionnaire or the Emotional Eating Questionnaire—to identify emotional eaters before they begin medication. This allows providers to build targeted behavioral support into the patient's care plan from day one, maximizing the likelihood of weight-loss success.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare provider before starting, stopping, or changing any medication or weight-loss treatment plan.